{
    "nct_id": "NCT03411915",
    "official_title": "A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAbÂ®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)",
    "inclusion_criteria": "* Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization [WHO] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past 12 months\n* Histologically confirmed GIST that is locally advanced or metastatic\n* NET and GIST tumors must be unresectable\n* NET subjects must have progressed on or been ineligible for treatment with somatostatin analogues (SSA) and at least one other FDA-approved targeted therapy (everolimus or sunitinib).\n* GIST subjects must have previously received all FDA-approved therapies (imatinib mesylate, sunitinib malate, and regorafenib) for which they are eligible\n* Must have disease measurable by RECIST 1.1 criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Diagnosis of high-grade (WHO Grade 3) or poorly differentiated NET; high-grade neuroendocrine carcinoma; large cell neuroendocrine carcinoma, small cell carcinoma, or mixed small and large cell carcinoma.\n* Subjects currently receiving anti-cancer therapies (other than SSAs, which may continue).\n* Subjects who have received anti-cancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, immunotherapy, etc.).\n* Must not be experiencing a Grade 3 or 4 toxicity from previous anti-cancer treatment\n* Must not be receiving other anti-cancer therapies (except somatostatin analogues, which may be allowed)\n* Must not have poorly controlled diabetes mellitus, known central nervous system involvement by malignant disease or insufficient bone marrow, renal, or hepatic function",
    "miscellaneous_criteria": ""
}